Biologic facts
BrandOrencia (Abatacept)
No biosimilar to Orencia is licensed. The 12-year reference exclusivity date of 12/2017 is an estimate from first approval; the Purple Book does not list patents, which can protect a biologic longer.
Orencia was first approved by the FDA in 2005; the application holder is Bristol-Myers Squibb Company.
The latest NADAC for ORENCIA CLICKJECT 125 MG/ML is $1,470.99 per mL (as of 10/28/2026).
Holder Bristol-Myers Squibb CompanyApproved 2005
01Exclusivity
When biosimilar competition can legally begin. The Purple Book lists reference exclusivity but not patents, which can protect a biologic longer.
- Patents
- Not listed in the Purple Book Purple Book
- Reference exclusivity
- 12/201712-year estimate from first approval Purple Book
02Competition
- Biosimilars
- No biosimilar approved Purple Book
Every makerEach licensed product and biosimilar maker.
PrescribersWho prescribes it, from Medicare data.
Spend and safetyMedicare Part B spend and safety reports.
Available in the full Orencia profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $1,470.99 per mLORENCIA CLICKJECT 125 MG/ML, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Bristol-Myers Squibb Company Purple Book
- First approved
- 2005 Purple Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.